Prostate cancer chemoprevention by natural agents: Clinical evidence and potential implications

被引:40
|
作者
Chhabra, Gagan [1 ]
Singh, Chandra K. [1 ]
Ndiaye, Mary Ann [1 ]
Fedorowicz, Samantha [1 ]
Molot, Arielle [1 ]
Ahmad, Nihal [1 ,2 ]
机构
[1] Univ Wisconsin, Dept Dermatol, Madison, WI USA
[2] William S Middleton VA Med Ctr, Madison, WI USA
基金
美国国家卫生研究院;
关键词
Prostate cancer; Chemoprevention; Natural agents; Clinical trials; GREEN-TEA-CATECHINS; BASE-LINE CHARACTERISTICS; PLACEBO-CONTROLLED TRIAL; VITAMIN-E; SELENIUM SUPPLEMENTATION; PREVENTION TRIAL; HIGH-RISK; INTRAEPITHELIAL NEOPLASIA; NUTRITIONAL PREVENTION; DOUBLE-BLIND;
D O I
10.1016/j.canlet.2018.02.025
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Prostate cancer (PCa) is the most common non-skin cancer and the second leading cause of cancer related deaths in American men. Due to its long latency period, PCa is considered as an ideal cancer type for chemopreventive interventions. Chemopreventive agents include various natural or synthetic agents that prevent or delay cancer development, progression and/or recurrence. Pre-clinical studies suggest that many natural products and dietary agents have chemopreventive properties. However, a limited number of these agents have been tested in clinical trials, with varying success. In this review, we have discussed the available clinical studies regarding the efficacy of natural chemopreventive agents against PCa, including tea polyphenols, selenium, soy proteins, vitamins and resveratrol. We have also provided a discussion on the clinical challenges and opportunities for the potential use of chemopreventive agents against PCa. Based on available literature, it appears that the variable outcomes of the chemopreventive clinical studies necessitate a need for additional studies with more rigorous designs and methodical interpretations in order to measure the potential of the natural agents against PCa. Published by Elsevier B.V.
引用
收藏
页码:9 / 18
页数:10
相关论文
共 50 条
  • [41] Chemoprevention of prostate cancer
    Schmitz-Drager, B. J.
    Lummen, G.
    Schafer, R. M.
    UROLOGE, 2007, 46 (06): : 611 - +
  • [42] Chemoprevention of prostate cancer
    Thompson, IM
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2004, 22 (04) : 321 - 321
  • [43] Chemoprevention of prostate cancer
    Rittmaster, Roger S.
    ACTA ONCOLOGICA, 2011, 50 : 127 - 136
  • [44] Chemoprevention for prostate cancer
    Balakrishnan, L
    EUROPEAN JOURNAL OF CANCER, 2005, 41 (11) : 1498 - 1498
  • [45] Chemoprevention in prostate cancer
    Parnes, Howard L.
    Figg, William D.
    PHARMACOTHERAPY, 2006, 26 (10): : 1533 - 1533
  • [46] Chemoprevention of Prostate Cancer
    Thompson, Ian M.
    Tangen, Catherine M.
    Goodman, Phyllis J.
    Lucia, M. Scott
    Klein, Eric A.
    JOURNAL OF UROLOGY, 2009, 182 (02): : 499 - 507
  • [47] Chemoprevention of prostate cancer
    Kucuk, O
    CANCER AND METASTASIS REVIEWS, 2002, 21 (02) : 111 - 124
  • [48] Chemoprevention of Prostate Cancer
    Hammerer, P.
    AKTUELLE UROLOGIE, 2012, 43 (03)
  • [49] Chemoprevention of prostate cancer
    Schulman, Claude
    ANNALS OF ONCOLOGY, 2004, 15 : 7 - 7
  • [50] Chemoprevention of prostate cancer
    Klein, EA
    ANNUAL REVIEW OF MEDICINE, 2006, 57 : 49 - 63